Here, though analysis of patient biospecimens, in vitro and in vivo models, we demonstrate: 1) associations between CCL2 and HGF expression in breast carcinoma tissues, 2) cooperativity between CCL2 and HGF signaling in regulation of breast cancer cell growth, survival, invasion, and metabolism, and 3) therapeutic effects in animal models of DCIS progression when CCR2 and MET are targeted. The gene discussed is MET; the disease is ductal breast carcinoma in situ.